Volume 50
Number 1
July 1996

MOLECULAR PHARMACOLOGY

Contents

ACCELERATED COMMUNICATIONS

ARTICLES

Continued

MOLECULAR PHARMACOLOGY (MOL/ISSN 0026-895X) is an official publication of The American Society for Pharmacology and Experimental Therapeutics and is published monthly, two volumes a year, beginning in January and July, by Williams & Wilkins, 351 West Camden Street, Baltimore, MD 21201-2436. Periodicals Postage paid at Baltimore, MD and at additional mailing offices. POSTMASTER: Send address changes to MOLECULAR PHARMACOLOGY, 351 West Camden Street, Baltimore, MD 21201-2436. **Subscription Rates: U.S.:** *Personal* $115; *Institutional* $250; *Single copy* $23. **Outside the U.S., except for Japan:** *Personal* $150; *Institutional* $285; *Single copy* $26. Foreign prices exclude Japan. **See Information for Subscribers for detailed instructions.** The GST Tax Number for Canadian subscribers is 123394371. Country of origin USA. C.P.C. Int'l Publication Mail #0059870. PRICES ARE SUBJECT TO CHANGE. Indexed by *Index Medicus*, *Current Contents* (*Life Sciences*), *Excerpta Medica*, *Reference Update/Research Information Systems*, and *Current Awareness in Biological Sciences*.

Continued

Continued

About the cover: Targeting of delta opioid receptor to surface membranes. COS-1 cells were transfected with a mouse δ-opioid receptor mutant (D128A), for which the conserved aspartate in the third membrane domain is replaced by alanine. Cells were double-labeled with fluorescein-congugated concanavalin A to label the plasma membrane (*green*) and with an anti-δ-opioid receptor antibody followed by rhodamine-conjugated streptavidin (*red*). *Yellow* shows the region of colocalization. This mutant exhibited reduced expression and subtle changes in its ability to bind certain agonist ligands. From Befort, K., L. Tabbara, S. Bausch, C. Chavkin, C. Evans, and B. Kieffer. The conserved aspartate residue in the third putative transmembrane domain of the δ-opioid receptor is not the anionic counterpart for cationic opiate binding but is a constituent of the receptor binding site. *Mol. Pharmacol.* **49:** 216–223 (1996).